Literature DB >> 1370673

Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP).

D Asselineau1, M T Cavey, B Shroot, M Darmon.   

Abstract

The role played by cytosolic retinoic acid-binding proteins (CRABP) in the control of differentiation and morphogenesis by retinoids remains unclear, which contrasts with the presence of these binding proteins in tissues known to be targets for retinoic acid effects. Human epidermis represents a good system to address this question because 1) the effect of retinoids on keratinocyte differentiation is well documented; 2) epidermis contains CRABP, and the amount of these proteins is modulated both by keratinization and retinoids; 3) the architecture of epidermis obtained in vitro by growing adult human keratinocytes on a dermal substrate can be modulated by retinoids added to the culture medium in a dose-dependent manner; and 4) most markers of epidermal differentiation are also modulated by retinoids in a dose-dependent manner. In this study, we compared, in dose-response experiments, the biologic activities of retinoic acid and CD271, a substance unable to bind to CRABP, but able to bind to nuclear retinoic acid receptors (RAR). Our results show that retinoic acid and CD271 exert similar controls on epidermal morphogenesis and keratinocyte differentiation, as shown by the inhibition of the synthesis of suprabasal keratins, filaggrin, and transglutaminase. Therefore, we exclude a qualitative role for CRABP in the control exerted by retinoids on the differentiation and morphogenesis of cultured human keratinocytes. Instead of being involved in the pathway via which retinoids control epidermal gene expression, CRABP might regulate the amount of intracellular-active retinoic acid and thus control quantitatively the intensity of biologic effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370673     DOI: 10.1111/1523-1747.ep12555633

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Multistep production of bioengineered skin substitutes: sequential modulation of culture conditions.

Authors:  F A Auger; R Pouliot; N Tremblay; R Guignard; P Noël; J Juhasz; L Germain; F Goulet
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

2.  Topical all-trans retinoic acid (RA) induces an early, coordinated increase in RA-inducible skin-specific gene/psoriasin and cellular RA-binding protein II mRNA levels which precedes skin erythema.

Authors:  C C Zouboulis; J J Voorhees; C E Orfanos; A Tavakkol
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

Review 3.  Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: clinical and fundamental applications.

Authors:  F A Auger; M Rouabhia; F Goulet; F Berthod; V Moulin; L Germain
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

4.  Plantar warts treated with topical adapalene.

Authors:  Ramji Gupta
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

Review 5.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 6.  Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne.

Authors:  R N Brogden; K E Goa
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

7.  Topical adapalene in the treatment of plantar warts; randomized comparative open trial in comparison with cryo-therapy.

Authors:  Ramji Gupta; Sarthak Gupta
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.